BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

Company Overview

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.

BioMarin’s marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates. The company also markets Roctavian, a gene therapy for adults with severe hemophilia A, in certain markets. Its research and development programs continue to focus on genetic medicines, enzyme replacement therapies, and other treatments for rare diseases.

BioMarin serves patients and healthcare providers internationally, with commercial operations spanning North America, Europe, Latin America, and other global markets. Alexander Hardy has served as the company’s president and chief executive officer since 2023, bringing prior leadership experience from the biotechnology and pharmaceutical industry.

Key Stats

• Today's Range: $65.72 to $66.88
• 50-Day Range: $58.40 to $70.24
• 52-Week Range: $49.26 to $70.98
• Volume: 1.34 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $12.85 billion
• P/E Ratio: 179.49
• Dividend Yield: N/A
• Price Target: $89.17
• Consensus Rating: Moderate Buy

BioMarin Pharmaceutical Stock Analysis - MarketRank™

BioMarin Pharmaceutical scored higher than 92% of companies evaluated by MarketBeat, and ranked 21st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 2 strong buy ratings, 14 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

BioMarin Pharmaceutical has a consensus price target of $89.17, representing about 34.3% upside from its current price of $66.41.

Amount of Analyst Coverage

BioMarin Pharmaceutical has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 32.93%

Earnings Growth

Earnings for BioMarin Pharmaceutical are expected to grow by 32.93% in the coming year, from $4.10 to $5.45 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioMarin Pharmaceutical is 179.49, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.99.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioMarin Pharmaceutical is 179.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.30.

Price to Earnings Growth Ratio

BioMarin Pharmaceutical has a PEG Ratio of 0.47. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

BioMarin Pharmaceutical has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.14% of the float of BioMarin Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 5.76.

Change versus previous month

Short interest in BioMarin Pharmaceutical has recently decreased by 3.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioMarin Pharmaceutical does not currently pay a dividend.

Dividend Growth

BioMarin Pharmaceutical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.70

News Sentiment

BioMarin Pharmaceutical has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for BioMarin Pharmaceutical this week, compared to 9 articles on an average week.

Search Interest

Only 11 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

MarketBeat Follows

8 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.68% of the stock of BioMarin Pharmaceutical is held by insiders.

Percentage Held by Institutions

98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/15/2026
• Next Earnings (Estimated): 10/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BMRN
• CIK: 1048477
• Web: www.biomarin.com
• Phone: (415) 506-6700
• Fax: 415-382-7889
• Employees: 3,221
• Year Founded: 1997

Price Target and Rating

• Average Price Target for BioMarin Pharmaceutical: $89.17
• High Price Target: $124.00
• Low Price Target: $60.00
• Potential Upside/Downside: +34.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.74
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.37
• Trailing P/E Ratio: 179.49
• Forward P/E Ratio: 16.20
• P/E Growth: 0.47
• Net Income: $348.90 million
• Net Margins: 2.14%
• Pretax Margin: 4.38%
• Return on Equity: 5.32%
• Return on Assets: 3.69%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 2.39
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $3.22 billion
• Price / Sales: 3.99
• Cash Flow: $2.88 per share
• Price / Cash Flow: 23.02
• Book Value: $31.68 per share
• Price / Book: 2.10

Miscellaneous

• Outstanding Shares: 193,570,000
• Free Float: 192,258,000
• Market Cap: $12.85 billion
• Optionable: Optionable
• Beta: 0.24